China, Oct. 15 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Obinutuzumab-β for relapsed/refractory primary membranous nephropathy: a prospective open-label single-center clinical study'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600134364
Registration Time: 2026/10/14
Type: Interventional study
Primary Sponsor: The Affiliated Hospital of Southwest Medical University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=346489
Published by HT Digital Content Services with permission from Health Daily Digest....